| Literature DB >> 30273334 |
Sangshin Park1,2, Anon Srikiatkhachorn3, Siripen Kalayanarooj4, Louis Macareo5, Sharone Green6, Jennifer F Friedman1,2, Alan L Rothman3.
Abstract
BACKGROUND: Early recognition of dengue, particularly patients at risk for plasma leakage, is important to clinical management. The objective of this study was to build predictive models for dengue, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS) using structural equation modelling (SEM), a statistical method that evaluates mechanistic pathways. METHODS/Entities:
Mesh:
Year: 2018 PMID: 30273334 PMCID: PMC6181434 DOI: 10.1371/journal.pntd.0006799
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Study participants.
Fig 2(A) Hypothesized pathways for developing dengue, DHF, or DSS and structural equation models predicting (B) dengue, (C) DHF, and (D) DSS. (B) The model fits were RMSEA = 0.057 and CFI = 0.979. (C) The model fits were RMSEA = 0.000 and CFI = 1.000. (D) The model fits were RMSEA = 0.095 and CFI = 0.937. Arrows indicate hypothetically significant positive or negative associations in (A). Solid and dotted arrows indicate significant positive and negative associations, respectively, in (B), (C), and (D). Unstandardized (= B) and standardized (= β) coefficients are shown next to the arrows. Correlations were omitted from the diagram. Unit: age, y; AST, U/mL; ALT, U/mL; WBC, cells/mm3; Lymphocytes, %; Albumin, g/dL; Hematocrit, %; Platelets, cells/mm3; Tourniquet test, petechiae/in2. AST, ALT, WBC, hematocrit, platelets, and tourniquet test were ln-transformed. Thickness of arrows was determined by standardized coefficients. *P value <0.05, **P value <0.01, ***P value <0.001.
Characteristics of study participants (n = 257).
| Non-dengue | Dengue, | DHF, | DSS | ||
|---|---|---|---|---|---|
| n | 101 (39.3%) | 105 (40.9%) | 42 (16.3%) | 9 (3.5%) | |
| Sex (= girl) | 51 (50.5%) | 51 (48.6%) | 14 (33.3%) | 8 (88.9%) | 0.018 |
| Age, yr | 6.8 (6.2–7.3) | 8.9 (8.4–9.5)b | 9.3 (8.3–10.4)b | 8.5 (6.1–10.9) | <0.001 |
| At fever day -3 | |||||
| AST, U/mLa | 35.8 (33.4–38.3) | 45.9 (42.0–50.3)b | 47.7 (39.8–57.2)b | 65.7 (33.5–128.1)b | <0.001 |
| ALT, U/mLa | 18.6 (17.2–20.1) | 23.0 (20.6–25.7)b | 23.3 (18.9–28.7) | 31.7 (15.4–64.4)b | 0.003 |
| WBC, 1,000 cells/mm3,a | 7.4 (6.7–8.2) | 4.2 (3.8–4.5)b | 4.0 (3.4–4.6)b | 4.2 (2.9–6.1)b | <0.001 |
| Lymphocytes, % | 27.1 (23.5–30.7) | 24.3 (21.6–27.0) | 23.6 (17.9–29.4) | 24.6 (9.3–39.8) | 0.57 |
| Albumin, g/dL | 4.6 (4.6–4.7) | 4.7 (4.6–4.8) | 4.8 (4.6–4.9) | 4.4 (4.1–4.8) | 0.33 |
| Hematocrit, %a | 38.3 (37.7–38.8) | 38.9 (38.3–39.5) | 39.8 (38.8–40.8)b | 37.4 (34.8–40.2) | 0.031 |
| Platelets, 1,000 cells/mm3,a | 228 (212–244) | 190 (176–206)b | 167 (136–205)b | 158 (114–219) | <0.001 |
| Tourniquet test, petechiae/in2,a | 4.6 (3.6–5.8) | 6.4 (5.1–7.9) | 9.9 (7.4–13.1)b | 8.4 (4.9–13.9) | 0.002 |
| At fever day -1 | |||||
| AST, U/mLa | 37.6 (33.8–41.7) | 70.2 (61.4–80.2)b | 95.1 (76.4–118.3)b,c | 137.5 (75.2–250.8)b,c | <0.001 |
| ALT, U/mLa | 19.1 (17.3–21.1) | 33.5 (29.0–38.7)b | 38.9 (30.5–49.4)b | 60.6 (23.8–152.0)b | <0.001 |
| WBC, 1,000 cells/mm3,a | 5.3 (4.9–5.9) | 2.7 (2.5–2.9)b | 2.7 (2.4–3.1)b | 4.3 (2.8–6.5)c,d | <0.001 |
| Lymphocytes, % | 38.7 (35.2–42.1) | 38.7 (36.3–41.2) | 33.5 (29.2–37.7) | 35.9 (23.8–48.0) | 0.23 |
| Albumin, g/dL | 4.4 (4.4–4.5) | 4.4 (4.3–4.5) | 4.4 (4.2–4.6) | 4.0 (3.4–4.5)b | 0.06 |
| Hematocrit, %a | 37.3 (36.6–38.1) | 38.4 (37.7–39.2) | 40.6 (39.3–41.8)b,c | 42.0 (38.1–46.3)b | <0.001 |
| Platelets, 1,000 cells/mm3,a | 206 (190–223) | 140 (128–153)b | 110 (93–131)b,c | 69 (40–118)b,c,d | <0.001 |
| Tourniquet test, petechiae/in2,a | 3.3 (2.4–4.3) | 8.4 (6.7–10.5)b | 12.2 (9.6–15.4)b | 18.9 (16.2–22.1)b | <0.001 |
Data represent arithmetic or geometrica mean (95% confidence interval) or n (proportion, %). b, c, and d Significantly different from non-dengue, dengue but non-DHF, and DHF but non-DSS, respectively, P value <0.05. P values were estimated by Fisher’s exact tests or analysis of variance followed by Bonferroni post hoc test.
Total effect of predictors at fever day -3 in developing dengue, DHF, and DSS based on SEMs.
| Outcome | Predictor | Unstandardized coefficient (= | Standardized coefficient (= β) | Odds ratio (95% confidence interval) | |
|---|---|---|---|---|---|
| Dengue | |||||
| Age, y | 0.298 | 0.140 | 1.35 (1.20–1.52) | <0.001 | |
| AST, U/mL | 1.191 | 0.265 | 3.29 (2.30–4.70) | <0.001 | |
| WBC, cells/mm3 | -1.422 | -0.378 | 0.24 (0.14–0.42) | <0.001 | |
| Lymphocytes, % | -0.009 | -0.067 | 0.991 (0.983–0.999) | 0.034 | |
| Platelets, cells/mm3 | -0.199 | -0.042 | 0.82 (0.72–0.93) | 0.002 | |
| Tourniquet test, petechiae/in2 | 0.271 | 0.117 | 1.31 (1.07–1.60) | 0.008 | |
| DHF | |||||
| Age, y | 0.110 | 0.079 | 1.12 (1.06–1.18) | <0.001 | |
| AST, U/mL | 0.380 | 0.129 | 1.46 (1.10–1.94) | 0.008 | |
| WBC, cells/mm3 | -0.352 | -0.135 | 0.70 (0.58–0.85) | <0.001 | |
| Hematocrit, % | 2.453 | 0.138 | 11.62 (2.11–64.08) | 0.005 | |
| Platelets, cells/mm3 | -0.289 | -0.092 | 0.75 (0.63–0.89) | 0.001 | |
| Tourniquet test, petechiae/in2 | 0.305 | 0.205 | 1.36 (1.10–1.67) | 0.004 | |
| DSS | |||||
| Age, y | -0.012 | -0.009 | 0.99 (0.95–1.03) | 0.52 | |
| AST, U/mL | 0.652 | 0.237 | 1.92 (1.07–3.44) | 0.028 | |
| WBC, cells/mm3 | 0.339 | 0.139 | 1.40 (0.80–2.45) | 0.23 | |
| Lymphocytes, % | 0.007 | 0.087 | 1.007 (0.999–1.015) | 0.11 | |
| Platelets, cells/mm3 | -0.527 | -0.184 | 0.59 (0.42–0.83) | 0.003 | |
| Tourniquet test, petechiae/in2 | -0.081 | -0.063 | 0.92 (0.84–1.01) | 0.08 |
Total effect was the sum of direct and indirect effects. AST, WBC, hematocrit, platelets, and tourniquet test were ln-transformed. AST, ALT, WBC, hematocrit, platelets, and tourniquet test were ln-transformed.
Fig 3ROC curves for external validation employing fever days: (A) dengue, (B) DHF, and (C) DSS. n = 878 (nfever day -3 = 143, nfever day -2 = 366, nfever day -1 = 590, and nfever day 0 = 617).
Fig 4ROC curves for external validation employing study days: (A) dengue, (B) DHF, and (C) DSS. n = 896 (nstudy day 1 = 880, nstudy day 2 = 579, and nstudy day 3 = 318).
Fig 5ROC curves for external validation employing illness days: (A) dengue, (B) DHF, and (C) DSS. n = 885 (nillness day 2 = 267, nillness day 3 = 481, nillness day 4 = 572, and nillness day 5 = 377).